Chemical inhibitors of NMU-25 employ various mechanisms to obstruct the protein's function. BIBN 4096 BS, PD 168368, SB-222200, SB-674042, SB-612111, T-2328, JNJ-5207787, and JNJ-17203212 are chemicals that directly target the neuromedin U receptor, which is the primary receptor through which NMU-25 exerts its effects. BIBN 4096 BS can inhibit NMU-25 by blocking the receptor interactions that NMU-25 relies on to initiate signaling. PD 168368 functions similarly, antagonizing the neuromedin U receptor to prevent NMU-25 from triggering its typical biological responses. SB-222200 and SB-674042 act as antagonists to this receptor, thereby blocking the downstream signaling events NMU-25 would usually activate. SB-612111 prevents NMU-25 from binding to its receptor, thwarting the subsequent signaling cascade. T-2328 also blocks the receptor targeted by NMU-25, preventing the protein from instigating its signaling pathway. JNJ-5207787 and JNJ-17203212 inhibit NMU-25 by binding with high affinity to its receptor, thus directly impeding NMU-25's receptor-mediated action.
On the other hand, Ononetin, Lestaurtinib, Erlotinib, and Sorafenib work by inhibiting downstream or parallel pathways to the NMU-25 signaling process. Ononetin interacts with kinase pathways that are activated following NMU-25 receptor interaction, thereby indirectly inhibiting the protein's effects. Lestaurtinib targets intracellular signaling mechanisms such as the JAK/STAT pathway, which NMU-25 may utilize for its biological activities, leading to an inhibition of NMU-25's function. Erlotinib inhibits NMU-25 by obstructing the epidermal growth factor receptor (EGFR) pathway, which, when inhibited, can reduce the functional activity of NMU-25. Lastly, Sorafenib blocks the RAF/MEK/ERK pathway, which is a critical signaling route that NMU-25 may influence, thus obstructing NMU-25's activities. Each of these inhibitors disrupts the signaling pathways in a manner that results in the functional inhibition of NMU-25, preventing it from carrying out its role in cellular processes.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
JNJ 17203212 | 821768-06-3 | sc-204024 sc-204024A | 10 mg 50 mg | $185.00 $781.00 | ||
JNJ-17203212 can inhibit NMU-25 by binding to its receptor with high affinity, thereby inhibiting NMU-25 induced receptor activation and signaling. | ||||||
Lestaurtinib | 111358-88-4 | sc-218657 sc-218657A sc-218657B | 1 mg 5 mg 10 mg | $275.00 $326.00 $612.00 | 3 | |
Lestaurtinib can inhibit NMU-25 by targeting the intracellular signaling pathways such as JAK/STAT, which are involved in the signaling cascades of NMU-25, leading to inhibition of NMU-25's biological activities. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib can inhibit NMU-25 indirectly by inhibiting the epidermal growth factor receptor (EGFR) pathway which can have downstream effects on the signaling pathways NMU-25 is involved in, leading to its functional inhibition. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib can inhibit NMU-25 by blocking the RAF/MEK/ERK pathway, which may be downstream or in parallel to NMU-25 signaling, thus inhibiting the functional activity of NMU-25. | ||||||